• EnglishEnglish
    • Deutsch Deutsch
    • Italiano Italiano
    • Français Français
    • 日本語 日本語
    • 한국어 한국어

CISEMA - China Certification, Purchasing and Quality Assurance

  • Services
    • NMPA Registration – Medical Devices and IVDs
    • NMPA Registration & DMF – Pharmaceuticals
    • NMPA Registration – Cosmetics
    • NMPA Registration – Health Food
    • CML (China Manufacture Licence) – Pressure vessels
    • CCC (China Compulsory Certification) – Industrial and consumer goods
    • Others
      • Sourcing and Quality Control
      • Logistics and Customs Support
      • Sales Support
  • About us
    • Partners
    • Company Profile
    • Testimonials
  • Locations
  • Events
    • Trade Fairs & Conferences
    • Seminars
    • Webinars
  • News & Knowledge
    • Regulatory News
      • Medical Devices and IVDs
      • Cosmetics
      • Pharmaceuticals & DMF
      • CCC
      • Pressure Vessels
    • Whitepapers
    • FAQ – NMPA Registration – Medical Devices and IVDs
    • Others
      • Publications
      • Online Shop
Contact
  • Home
  • News
  • News
  • NMPA Registration in China
  • Medical Device
  • China OEM Production of High-Risk Implants Soon to be Prohibited

China OEM Production of High-Risk Implants Soon to be Prohibited

Monday, 20 December 2021 / Published in Medical Device, News, NMPA Registration in China

China OEM Production of High-Risk Implants Soon to be Prohibited

On November 19, 2021, the NMPA (National Medical Products Administration) issued the draft catalogue of medical device products to be prohibited from OEM (Original Entrusted Manufacture) production in China.

The catalogue was first issued in April 2005, and the revised version was later issued (No.18 – 2014) on September 26, 2014. According to the Order 739 implemented in June 1, 2021, the registrants and filers can self-manufacture medical devices or entrust a qualified manufacturer for production in general. However, the Order 739 specified that the manufacturing of high-risk medical implants cannot be entrusted to other parties.

22 high-risk medical implants have been added in the draft catalogue as below:

Active implantable medical device

1. Implantable Cardiac Pacemaker

2. Implantable cardioverter defibrillator

3. Implantable cardiac contractile force regulator

4. Implantable circulatory support devices

Non-active implantable medical device

1. Sports injury soft tissue replacement implant (Allograft)

2. Acrylic bone cement

3. Allogeneic bone repair materials

4. Dural membrane patch

5. Aneurysm clip

6. Intracranial stent system

7. Intracranial embolization equipment

8. Intracranial coil system

9. Intracranial aneurysm blood flow guide device

10. Cardiovascular implants (except peripheral vascular stents)

11. Plastic filling materials

12. Plastic injection fillers

13. Breast implants

14. Tissue engineering scaffold materials

Other medical devices not allowed for sub-contract production

1. Absorbable surgical anti-adhesion dressing

2. Tissue engineered biological amniotic membrane

3. Tissue engineering cornea stroma

4. Vaginal mesh and pelvic floor mesh

Because the manufacturing of medical devices in China are much more mature than before, the NMPA has removed some products from the previous catalogue in this draft that would allow the OEM production in future.

On November 15, 2021, the NMPA issued a draft guideline for writing OEM quality agreements in China. According to the draft guideline, registrants or filers shall sign this agreement with OEM manufacturers to specify the rights, obligations and responsibilities of both sides in the entire process of achieving product quality. Read our separate blog post for more detailed information.

By Alice Liu and Jacky Li. Contact Cisema if you would like to learn more.

Tagged under: Implants, OEM production, Order 739

What you can read next

15 New NMPA Technical Review Guidelines for Medical Device Registrations
NMPA emergency approval channels for Covid-19 response now closed
Registration of Infant Formula Milk Powder in China

Search

Categories

  • Fairs & Events
  • News
    • CCC
    • CEL
    • CML, SELO
    • Medical Devices Listing in Hong Kong
    • NMPA Registration in China
      • Cosmetics
      • Health Food
      • Medical Device
      • Pharmaceuticals & DMF
    • RoHS
  • Publications
  • Seminars
  • Webinars

Recent Posts

  • clinical trials locally applied locally acting products

    New Guidelines on Clinical Trials of Locally Applied, Locally Acting Products

    Guidelines for clinical trials of locally appli...
  • medical device naming rules china

    China Medical Device Naming Rules Updated

    Medical device naming rules for China have been...
  • medical device qms audit

    Medical device QMS audit guidelines for product registration are open for comment

    China’s NMPA has issued draft guidelines on med...
  • china compulsory certificate

    Cisema Webinar: Certification in China – China Compulsory Certificate (CCC)

    The China Compulsory Certificate (CCC) is a man...
  • china gmp for pharmaceutical packaging

    China GMP for Pharmaceutical Packaging Materials (Draft for comments)

    A China Good Manufacturing Practices (GMP) on P...

Archive

Cisema

With twelve locations and over ninety highly qualified employees, Cisema can offer you optimal support in China.

Services

  • Certification
  • Sourcing and Quality Control
  • Logistics and Customs Support
  • Sales Support

Dialogue

  • Contact us
  • Newsletter Signup
  • Events
  • News & Knowledge
  • Partners

Company

  • GTC
  • Privacy Statement
  • Legal Notice
  • About us
  • Locations
  • GET SOCIAL

© 2021 Cisema. All rights reserved.

TOP
Cookies on Cisema
Learn more about Cisema's Privacy Policy.